ライフサイエンスコーパス: QOL

1 QOL did not differ from that of the general population,

2 QOL evaluation was conducted in survivors from a large c

3 QOL improved in patients treated with LS + inulin compar

4 QOL is impaired with endotherapy, but alimentary satisfa

5 QOL is significantly impaired after caustic ingestion.

6 QOL issues should not influence the emergency surgical s

7 QOL measures were not significantly different from basel

8 QOL of food-allergic children undergoing OIT improves si

9 QOL of patients with food allergy improves in some but d

10 QOL scores improved overall at 1 year (p < 0.001), with

11 QOL scores using either instrument between the 2 groups

12 QOL was assessed using the 4 subscales of the Physical C

13 QOL was assessed using the EORTC QLQ-OG25 module, the SF

14 QOL was evaluated using the MD Anderson Dysphagia Invent

15 QOL was maintained throughout therapy.

16 P<0.001) and psychological (B=0.04, P<0.001) QOL.

17 ly higher satisfaction with their breast and QOL at each assessed time point, but IBR patients had st

18 ogists to help improve HNC complications and QOL for HNC survivors.

19 e Seattle Angina Questionnaire frequency and QOL scales.

20 raphics, medical history, health habits, and QOL.

21 Serum level of sex hormone and QOL questionnaires were also evaluated at the baseline a

22 ion (VO2, mL/kg/min; co-primary outcome) and QOL measured by the Minnesota Living with Heart Failure

23 y providers to improve clinical outcomes and QOL for patients with ESLD and reduce health care costs.

24 opening, risk of aspiration/penetration and QOL in HNC patients.

25 Pain perception and QOL were evaluated by using specific questionnaires.

26 stimated systolic pressure gradient (PG) and QOL score were significantly improved after sildenafil t

27 ation, 90-day hospital readmission rate, and QOL.

28 t on LT outcomes, hospital readmissions, and QOL suggests that the adoption of telemedicine has great

29 tients had stable long-term satisfaction and QOL postoperatively.

30 r ejection fraction, and clinical status and QOL showed favorable trends.

31 iation between depressive symptomatology and QOL in stroke survivor-care partner dyads.

32 association between depressive symptoms and QOL within survivor-care partner dyads, we used a tradit

33 aumatic stress disorder (PTSD) symptoms, and QOL 6 months post-transplant.

34 splant, we assessed mood, PTSD symptoms, and QOL with the Hospital Anxiety and Depression Scale and P

35 ported toxic effects between treatment arms, QOL analysis demonstrated a clinically meaningful declin

36 nd 3 months after HCT and caregiver-assessed QOL and mood at baseline and 2 weeks after HCT.

37 This study assessed QOL in GenTAC participants with MFS and identify associa

38 UAS may be a useful tool for assessing QOL in pediatric patients with chronic urticaria.

39 nd comorbid asthma completed the Mini Asthma QOL Questionnaire (miniAQLQ) and Asthma Control Test (AC

40 CRS-specific factors associated with asthma QOL or control or ESS outcomes.

41 Patient demographics and baseline QOL scores were comparable between the 74-Gy and 60-Gy a

42 Better QOL was independently associated with socioeconomic fact

43 tients experienced pain reduction and better QOL at day 10 after radiotherapy with further improvemen

44 ment goal was "to cure my cancer" had better QOL (B = 4.33; P = .03) and less anxiety (B = -1.39; P =

45 In bivariate analysis, predictors of better QOL included college education, marital status, higher h

46 Parents reported better QOL scores compared to their children at all stages of O

47 ome patients with low FAQLQ-PF score (better QOL) at baseline deteriorated.

48 of positive reframing was related to better QOL (B = 2.61; P < .001) and less depression (B = -0.78;

49 Active coping was associated with better QOL (B = 3.50; P < .001) and less depression (B = -1.01;

50 anean diet (aMED) was associated with better QOL and decreased pain, stiffness, disability, and depre

51 Some patients with better QOL at baseline might deteriorate during OIT.

52 To determine the association between QOL and visual function as measured by 24-2 and 10-2 VFs

53 rs after a JP or a SE for low rectal cancer, QOL, functional outcome, and complications are comparabl

54 ata to determine associations with caregiver QOL.

55 6, P < .01), indicating that worse caregiver QOL was significantly correlated with more depressive sy

56 signing interventions to improve caregivers' QOL, thereby maximizing their ability to care for childr

57 ific symptoms (CSI), and quality of life (CD-QOL).

58 Children QOL scores were compared to their parents.

59 KDQOL-36 and CKD-QOL measures generally discriminated better than generic

60 Results for static and CAT CKD-QOL forms were similar.

61 Two RV test results confirmed CKD-QOL improvements over the referent KDQOL scale.

62 pecific tests comparing validity favored CKD-QOL two-fold over KDQOL-36.

63 D-specific quality-of-life impact scale (CKD-QOL) with currently used measures.

64 ransplant) completed the kidney-specific CKD-QOL and Kidney Disease Quality of Life-36 (KDQOL-36) for

65 Validity tests compared the CKD-QOL, KDQOL-36 (Burden, Effects, and Symptoms/Problems su

66 QOL) scores by Japanese rhino-conjunctivitis QOL questionnaire (JRQLQ No1).

67 eptions Questionnaire), coping (Brief COPE), QOL (Functional Assessment of Cancer Therapy-General), a

68 ionships among prognostic awareness, coping, QOL, and mood in patients with newly diagnosed, incurabl

69 lts was correlated moderately with decreased QOL.

70 Defining QOL in pediatric CMT can help physicians monitor disease

71 Dermatology QOL instruments may measure general skin-specific, disea

72 aptive coping strategies in order to enhance QOL and mood.

73 eparately assessing functional vision and ER-QOL domains in children of any age and with any eye cond

74 l amblyopia affects functional vision and ER-QOL in children.

75 The primary outcome was the 6-month Euro QOL-5 Dimension (EQ-5D) index score (a measure of health

76 , did not provide an incremental benefit for QOL over 2 years of follow-up.

77 ritus (CP) has considerable implications for QOL.

78 h the newly developed SDQ and with a generic QOL tool (36-Item Short Form Health Survey).

79 ignificantly associated with disease-generic QOL (6 trials [n = 1334]; SMD, 0.18 [95% CI, -0.24 to 0.

80 c literature reviews and analysis of generic QOL measures to identify 6 domains relevant to QOL in ch

81 From baseline to week 12, GHS/QOL scores were maintained with both pembrolizumab plus

82 From baseline to week 21, GHS/QOL scores were better maintained with pembrolizumab plu

83 an baseline-to-week-15 change in QLQ-C30 GHS/QOL score was 6.9 (95% CI 3.3 to 10.6) for pembrolizumab

84 herapy maintained GHS/QOL, with improved GHS/QOL scores at week 21 in the pembrolizumab plus chemothe

85 30 global health status/quality of life (GHS/QOL) score, and time to deterioration in cough, chest pa

86 umab to standard chemotherapy maintained GHS/QOL, with improved GHS/QOL scores at week 21 in the pemb

87 the CarCGQoL (Caregivers Congenital Glaucoma QOL Questionnaire).

88 at 6 months (MD 11, 95% CI 4-19) and global QOL at 3 years (MD -13, 95% CI -22 to -5), than those wi

89 ents who had a PD demonstrated better global QOL, physical- and role-functioning scores at 5-years wh

90 ols, PD survivors demonstrated higher global QOL (78.7 vs 69.7, CR small, P < 0.001), physical (86.7

91 without long-term adverse effects on global QOL.

92 Predefined secondary end points were global QOL (GQOL; QLQ-C30), fatigue (FA; QLQ-C30), and emotiona

93 s. 29% [8 of 28]), and the mean change in GO-QOL overall score (13.79 points vs. 4.43 points) (P<=0.0

94 ophthalmopathy-specific quality-of-life (GO-QOL) questionnaire across trial visits (from baseline th

95 In the BAT group versus the control group, QOL score decreased (Delta = -14.1; 95% confidence inter

96 avoidant coping were associated with higher QOL and lower depressive symptoms at 24 weeks.

97 ted coping, which was associated with higher QOL and reduced depressive symptoms.

98 HR-QOL was assessed during a phone interview using the 36-I

99 Overall, ND-LLDs demonstrated acceptable HR-QOL after donation and are appropriate candidates for pa

100 to assess health-related quality of life (HR-QOL) in anonymous nondirected living liver donors (ND-LL

101 Long-term health-related quality of life (HR-QOL) of patients surviving the acute phase of purpura fu

102 utated patients have an impaired physical HR-QOL but a preserved mental health.

103 Long-term HR-QOL does not differ between patients surviving PF and th

104 ysfunction, nor does it significantly impact QOL.

105 Skin conditions can significantly impact QOL.

106 Patients with impaired QOL at baseline improve significantly despite the treatm

107 Attention to such symptoms may improve QOL and potentially improve chemoprevention adherence.

108 urable cancers, early integrated PC improved QOL and other salient outcomes, with differential effect

109 The THMP cohort also showed improved QOL in regards to physical function (P = 0.02) and gener

110 BAT was safe and significantly improved QOL, 6MHW, and NT-proBNP.

111 BAT was safe and significantly improved QOL, exercise capacity, and NT-proBNP.

112 ms and signs of dry eye as well as improving QOL in aging patients.

113 symptoms and TNSMS of JCP, and in improving QOL.

114 ng symptoms and SMS of JCP, and in improving QOL.

115 Secondary end points included change in QOL from baseline to week 24, change in depression per t

116 Comparing changes in QOL from baseline to day 42, responders had significantl

117 onstrated a clinically meaningful decline in QOL in the 74-Gy arm at 3 months, confirming the primary

118 18 to -0.86; P = .013), but no difference in QOL or anxiety.

119 ade 2-5 adverse events and no differences in QOL between arms.

120 omic variables, there were no differences in QOL or functional scores in the benign versus malignant

121 2,715/QALY because of minimal differences in QOL.

122 participants reported similar improvement in QOL during induction.

123 There was a trend toward improvement in QOL for ivabradine versus placebo (p = 0.053).

124 usual care) reported greater improvement in QOL from baseline to week 24 (1.59 v -3.40; P = .010) bu

125 adiotherapy one can expect an improvement in QOL is unknown.

126 There was a trend toward improvement in QOL parameters.

127 That was driven primarily by improvement in QOL scores in patients with high score (worse QOL) at ba

128 n BMI leads to a 10% adjusted improvement in QOL.

129 ts with lung cancer reported improvements in QOL and depression at 12 and 24 weeks, whereas usual car

130 n both study groups reported improvements in QOL and mood by week 12.

131 er radiotherapy with further improvements in QOL at day 42 in responders.

132 weak prediction for the percent reduction in QOL score with sildenafil treatment by plasma cGMP level

133 ctiveness by achieving certain thresholds in QOL, instrument costs, and postoperative outcomes.

134 To investigate QOL at days 10 and 42 after radiotherapy with a bone met

135 e points, with worse global quality of life (QOL) (MD -10, 95% CI -18 to -2) and dyspnea (MD 16, 95%

136 hospital readmissions, and quality of life (QOL) after liver transplantation (LT).

137 To compare quality of life (QOL) after radical prostatectomy, external beam radiothe

138 studies that found improved quality of life (QOL) after radiotherapy of bone metastases have small sa

139 s surgery (ESS) upon asthma quality of life (QOL) and asthma control using validated outcome metrics.

140 s <5 mm Hg mL(-1) m(-2)) on quality of life (QOL) and exercise performance (EP) >=1 year after transc

141 Our aim was to assess quality of life (QOL) and functionality in a large cohort of patients >/=

142 rin improves health-related quality of life (QOL) and MC mediator-related symptoms in patients with a

143 gnostic awareness and worse quality of life (QOL) and mood among patients with advanced cancer.

144 iative care (EIPC) improves quality of life (QOL) and mood for patients with advanced cancer.

145 ant care improves patients' quality of life (QOL) and symptom burden during hematopoietic stem-cell t

146 eas secondary outcomes were quality of life (QOL) and treatment safety.

147 scular events [MACCE]), and quality of life (QOL) during the 5-year follow-up.

148 l studies suggested reduced quality of life (QOL) for people with Marfan syndrome (MFS) compared with

149 ary end point was change in quality of life (QOL) from baseline to week 12, per scoring by the Functi

150 Quality of life (QOL) had declined due to severe pruritus, and they had s

151 damage with vision-related quality of life (QOL) has not been well studied.

152 New items summarizing quality of life (QOL) impact attributed to CKD across six QOL domains yie

153 ncer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the first EORT

154 tors such as depression and quality of life (QOL) in stroke survivor-care partner dyads.

155 Quality of life (QOL) is impaired in patients with food allergy and impro

156 emental effect on long-term quality of life (QOL) is uncertain.

157 swallowing dysfunction and quality of life (QOL) of adult patients with surgically corrected EA/TEF.

158 The quality of life (QOL) of both arms was broadly similar at 12 months.

159 r food allergy improves the quality of life (QOL) of children from parental perspective but little is

160 burden of burnout and poor quality of life (QOL) on surgeons relies on a thorough understanding of Q

161 visual analog scale (VAS), quality of life (QOL) scores by Japanese rhino-conjunctivitis QOL questio

162 nd satiety assessments, and quality of life (QOL) surveys, reported up to 3 months.

163 cally meaningful decline in quality of life (QOL) via the Functional Assessment of Cancer Therapy (FA

164 Quality of life (QOL) was below population means in 4 of 8 areas, but ali

165 Change in quality of life (QOL) was quantified based on the Yale-Brown Obsessive Co

166 pe natriuretic peptide, and quality of life (QOL) were assessed.

167 ening in menopause-specific quality of life (QOL) with treatment discontinuation at 1 year.

168 ent-centered communication, quality of life (QOL), and aggressive treatments in advanced cancer, yet

169 g clinical composite score, quality of life (QOL), and change in New York Heart Association (NYHA) fu

170 lable literature for costs, quality of life (QOL), and outcomes.

171 ity, radiographic response, quality of life (QOL), and plasma biomarkers.

172 eneric and disease-specific quality of life (QOL), and symptoms, with estimates of QOL translated to

173 CMT) reduces health-related quality of life (QOL), especially in children.

174 cancer and (b) evaluate the quality of life (QOL), pain perception, and efficacy in terms of time to

175 m burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment opt

176 stically reduces survivor's quality of life (QOL).

177 erving swallow function and quality of life (QOL).

178 T-C surveys to evaluate the quality of life (QOL).

179 volumes result in improved quality of life (QOL).

180 rvival (PFS), toxicity, and quality of life (QOL).

181 complications and decreased quality of life (QOL).

182 hological symptoms and poor quality of life (QOL).

183 rary DAPT and its impact on quality of life (QOL).

184 nd greatly influences their quality of life (QOL).

185 ptic neuritis episodes, and quality of life (QOL; based on the 54-item Multiple Sclerosis Quality of

186 -L1) status, and on-therapy quality-of-life (QOL) metrics using the Functional Assessment of Cancer T

187 global health status (GHS)/quality-of-life (QOL) score and time to deterioration of the composite of

188 iving with HF Questionnaire quality-of-life (QOL) score, and N-terminal pro-B-type natriuretic peptid

189 hocardiographic parameters, quality-of-life (QOL) score, and plasma cGMP concentrations before and af

190 Open colectomy cost more and achieved lower QOL than robotic and laparoscopic approaches.

191 raft dysfunction (n = 168) on 6 of the 10 LT-QOL scales.

192 sing the Lung Transplant Quality of Life (LT-QOL) Survey.

193 The LT-QOL contains 10 scales that measure symptoms, health per

194 The LT-QOL is a new, multidimensional instrument that character

195 At first visit, overall mean QOL scores were below the US population mean for both PC

196 ClinicalTrials.gov identifier NCT00782067]), QOL and symptom burden were assessed during treatment wi

197 dification of items from the pediatric Neuro-QOL measures.

198 Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), d

199 We studied the association of QOL with self-reported demographics, health behaviors, p

200 Key components in the development of QOL instruments include (i) instrument and conceptual fr

201 ation, performance status and all domains of QOL.

202 life (QOL), and symptoms, with estimates of QOL translated to units of the Functional Assessment of

203 as to determine the prevalence and impact of QOL of rhinitis in swimming compared to nonswimming athl

204 sion as a side effect of steroids or loss of QOL.

205 .3 to 15.9]) or disease-specific measures of QOL (11 trials [n = 2204]; SMD, 0.07 [95% CI, -0.09 to 0

206 mployment remained significant predictors of QOL.

207 Results of QOL questionnaires were compared to average values deter

208 unted the efficacy of sildenafil in terms of QOL improvement.

209 rgeons relies on a thorough understanding of QOL and burnout among the various surgical specialties.

210 (Y-BOCS) and the impact of complications on QOL was assessed.

211 however, patients reported minimal effect on QOL or day-to-day activities.

212 coping accounted for intervention effects on QOL and depressive symptoms.

213 treatment advances with possible effects on QOL have occurred.

214 ignificantly mediated the effects of EIPC on QOL (indirect effect, 1.27; 95% CI, 0.33 to 2.86) and de

215 gnals, and SABR had no detrimental impact on QOL.

216 tching intensity and impact of scratching on QOL) that accounted for 64.59% of the variance with a to

217 dy the change in Zva (baseline to 1 year) on QOL/EP.

218 d little decrement in swallowing function or QOL.

219 as reported in the no-CPM group in the other QOL domains.

220 icant heterogeneity in CTT, PAC-SYM, and PAC-QOL exists among studies.

221 essment of Constipation-Quality of Life (PAC-QOL) in adults diagnosed with functional constipation pe

222 ce, with older age associated with lower PAC-QOL scores.

223 rved in subjective symptoms (except a part), QOL scores (except a part), face scale and findings of n

224 were associated with improvements in patient QOL and symptom burden.

225 inically significant improvements in patient QOL at the 1- to 3-month follow-up (standardized mean di

226 We examined changes in patient QOL during OIT for food allergy.

227 mes and Measures: Primary: change in patient QOL from baseline to week 2; secondary: patient-assessed

228 t chronic itch greatly reduces the patients' QOL and impairs their daily activities.

229 s may be helpful for improving the patients' QOL through effective instruction and prevention of recu

230 itudinal analysis, to develop the final pCMT-QOL patient-reported outcome measure.

231 atric CMT-specific QOL outcome measure (pCMT-QOL).

232 nts to develop a working version of the pCMT-QOL measure.

233 The pCMT-QOL patient-reported outcome measure is a reliable, vali

234 Development and validation of the pCMT-QOL patient-reported outcome measure were iterative, inv

235 From 2010 to 2016, the pCMT-QOL working version was administered to 398 children age

236 minute walk distance, PROMIS-PF-6b, and PEmb-QOL scores improved over the course of 1 year in all gro

237 Quality of life was evaluated by PEmb-QOL scores at 30 days, 90 days, 180 days, 270 days, and

238 Parents perceive QOL to be better than the perception of the children.

239 ly positively associated with their physical QOL (B=0.28, P<0.001).

240 mized 1:1 to oral ranolazine versus placebo; QOL analyses included 2389 randomized subjects.

241 for burnout and more likely to report a poor QOL than attending surgeons.

242 va was 21% but remained associated with poor QOL/EP.

243 and 5.31 [95% CI, 3.58 to 7.04]), and poorer QOL (4.70 [95% CI, 2.82 to 6.58] and 5.22 [95% CI, 3.61

244 ervation and may maintain their prediagnosis QOL.

245 Prespecified co-primary QOL end points at 12 months, including the Atrial Fibril

246 The prespecified primary QOL measures were the Duke Activity Status Index and the

247 The primary QOL hypothesis predicted a clinically meaningful decline

248 4-Gy arm at 3 months, confirming the primary QOL hypothesis.

249 tionship, shared understanding of prognosis, QOL, and aggressive treatments and hospice use in the la

250 ve symptomatology and survivor psychological QOL (B=0.03, P<0.05) and moderated the association betwe

251 te the association of CPM with four BREAST-Q QOL domains.

252 elates with increased disability and reduced QOL.

253 he "eye" domain showed significantly reduced QOL in elite and nonelite swimmers compared to nonswimmi

254 scores indicate worse heart failure-related QOL; co-primary outcome).

255 However, its impact on health-related QOL and economic burden is not fully characterized.

256 lizumab improves or maintains health-related QOL compared with that for chemotherapy, and might repre

257 lid, and sensitive measure of health-related QOL for children with CMT.

258 h MFS in the GenTAC registry, health-related QOL was below the population norm.

259 Health-related QOL was evaluated using child- and adolescent-reported P

260 Improvement in NF2-related QOL and reduction in tinnitus-related distress were repo

261 hypothesis that patients with vision-related QOL disproportionate to their 24-2 VF status may exhibit

262 tagmus scales and an existing vision-related QOL tool, the Visual Function Questionnaire-25 (VFQ-25)

263 erstanding, patient-physician relationships, QOL, and aggressive treatments in the last 30 days of li

264 city, swallow function, and patient-reported QOL.

265 Self-reported QOL was completed using the European Organisation for Re

266 Caustic ingestion strongly affects patient's QOL but data on the topic is scarce in the literature.

267 nd their associations with disease severity, QOL, health, and functioning.

268 CP is associated with significant QOL impairment.

269 fe (QOL) impact attributed to CKD across six QOL domains yielded single impact scores from a six-item

270 the new approach to summarizing CKD-specific QOL impact performed better across multiple tests of val

271 studies to develop a pediatric CMT-specific QOL outcome measure (pCMT-QOL).

272 fic, disease-specific, or condition-specific QOL.

273 usion Negative changes in menopause-specific QOL influence a woman's decision to stop chemoprevention

274 n or, especially, overall menopause-specific QOL, was associated with early treatment discontinuation

275 radiotherapy with a bone metastases-specific QOL tool.

276 have developed a 29-item, nystagmus-specific QOL questionnaire (NYS-29) based on eudaimonic aspects o

277 unctioning as relating to nystagmus-specific QOL.

278 he Short-form 36 health survey and the stoma-QOL questionnaire.

279 tatus and treatment goal, coping strategies, QOL, and mood.

280 We investigated subjective symptoms, QOL scores, face scale, findings of nasal cavity and lab

281 e aim of the study was to evaluate long-term QOL after caustic ingestion.

282 patients and predicted unfavorable long-term QOL and EP.

283 Long-term QOL outcomes after PD for benign or malignant disease ar

284 associated with QOL decline, as well as the QOL issues most likely to affect caregivers of children

285 We identified items pertaining to QOL in children with CMT and conducted validation studie

286 for the role of spirituality in relation to QOL in medical-health contexts and the importance of exa

287 L measures to identify 6 domains relevant to QOL in children with CMT.

288 ine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (scores range from 0 to 100, with hig

289 th-related quality-of-life domain of the UFS-QOL questionnaire at 2 years was 84.6+/-21.5 in the myom

290 analysis, elevated Zva predicted unfavorable QOL (lower EuroQOL-5-dimensions-Utility Index, odds rati

291 patients in whom baseline Zva and follow-up QOL was prospectively assessed using EuroQOL-5-dimension

292 Binocular visual function (VF and VA) and VR QOL.

293 p between vision-related quality of life (VR QOL; Visual Activities Questionnaire [VAQ] and the 25-it

294 Primary end points were QOL scores and burnout rates that compared sex, age, lev

295 This study identified traits associated with QOL decline, as well as the QOL issues most likely to af

296 Outlier association with QOL was then assessed using a linear regression model, w

297 ted a terminally ill health status had worse QOL (unstandardized coefficient [B] = -6.88; P < .001),

298 OL scores in patients with high score (worse QOL) at baseline.

299 ygous PDE5A status had a significantly worse QOL score when compared to the wildtype group after sild

300 ion Prognostic awareness is related to worse QOL and mood in patients with newly diagnosed, incurable